<?xml version='1.0' encoding='utf-8'?>
<document id="18490437"><sentence text="A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro." /><sentence text="Although approaches to the prediction of drug-drug interactions (DDIs) arising via time-dependent inactivation have recently been developed, such approaches do not account for simple competitive inhibition or induction" /><sentence text=" Accordingly, these approaches do not provide accurate predictions of DDIs arising from simple competitive inhibition (e" /><sentence text="g" /><sentence text=", ketoconazole) or induction of cytochromes P450 (e"><entity charOffset="2-14" id="DDI-PubMed.18490437.s5.e0" text="ketoconazole" /></sentence><sentence text="g" /><sentence text=", phenytoin)"><entity charOffset="2-11" id="DDI-PubMed.18490437.s7.e0" text="phenytoin" /></sentence><sentence text=" In addition, methods that focus upon a single interaction mechanism are likely to yield misleading predictions in the face of mixed mechanisms (e" /><sentence text="g" /><sentence text=", ritonavir)"><entity charOffset="2-11" id="DDI-PubMed.18490437.s10.e0" text="ritonavir" /></sentence><sentence text=" As such, we have developed a more comprehensive mathematical model that accounts for the simultaneous influences of competitive inhibition, time-dependent inactivation, and induction of CYP3A in both the liver and intestine to provide a net drug-drug interaction prediction in terms of area under the concentration-time curve ratio" /><sentence text=" This model provides a framework by which readily obtained in vitro values for competitive inhibition, time-dependent inactivation and induction for the precipitant compound as well as literature values for f(m) and F(G) for the object drug can be used to provide quantitative predictions of DDIs" /><sentence text=" Using this model, DDIs arising via inactivation (e" /><sentence text="g" /><sentence text=", erythromycin) continue to be well predicted, whereas those arising via competitive inhibition (e"><entity charOffset="2-14" id="DDI-PubMed.18490437.s15.e0" text="erythromycin" /></sentence><sentence text="g" /><sentence text=", ketoconazole), induction (e"><entity charOffset="2-14" id="DDI-PubMed.18490437.s17.e0" text="ketoconazole" /></sentence><sentence text="g" /><sentence text=", phenytoin), and mixed mechanisms (e"><entity charOffset="2-11" id="DDI-PubMed.18490437.s19.e0" text="phenytoin" /></sentence><sentence text="g" /><sentence text=", ritonavir) are also predicted within the ranges reported in the clinic"><entity charOffset="2-11" id="DDI-PubMed.18490437.s21.e0" text="ritonavir" /></sentence><sentence text=" This comprehensive model quantitatively predicts clinical observations with reasonable accuracy and can be a valuable tool to evaluate candidate drugs and rationalize clinical DDIs" /><sentence text="" /></document>